Drug Discovery 2022: driving the next life science revolution


Dr Christophe Parsy
1Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond
Miss Sian Gardiner
Cardiff University
2Developing a robust vATPase activity assay to identify novel therapies for Alzheimer disease
Mrs Joanne Walter
Fida Biosystems ApS
3High-Throughput Detergent Screening for Membrane Protein solubilization using nanoliters of sample
Dr Iris Lavon
Hadassah Hebrew university medical organization
5From bench to beside toward a PET/CT guided androgen receptor antagonist treatment for glioblastoma
Mr Duncan Hall
6Transfection effi ciency of GFP- and mcherry-expressing HeLas evaluated on a microplate reader
Miss Josephine Pedder
Cardiff University
7Developing a high-throughput screening assay to support the drug discovery of γ-aminobutyric acid type A receptor (GABAAR) Positive Allosteric Modulators, for the treatment of Post-Partum Depression.
Dr Benjamin Durham
Charles River Laboratories
8A FACS assay to measure activation of human cytotoxic T-lymphocytes and CD73-dependent suppression by AMP
Dr Frances Hall
9Polo-like kinase 4 (PLK4) Safety Review – distilling the risks with a rapid augmented intelligence approach
Hosting a Presentation!
Profile Poster  
Dr Saman Honarnejad
Pivot Park Screening Centre
10Integration of MALDI-TOF Mass Spectrometry into a Fully Automated ultra-High Throughput Screening Platform
Dr Susanna Lovell
FOx Biosystems
11Using Fibre Optics based SPR to select for nanobodies in phage display
Dr Jamie Ware
12Development of a high-throughput quantitative biochemical ubiquitination assay platform to support E3 ligase recruitment and modulation drug discovery programmes
Dr Mark Chambers
Charles River Laboratories
13Identification of a potent, orally bioavailable small molecule PCSK9 inhibitor for lowering LDL-cholesterol
Dr Manal Mohammed
University of Westminster
14Genetic basis of phage-host interaction: Towards effective phage therapy of non-typhoidal Salmonella
Hosting a Presentation!
Profile Poster  
Dr Grainne Gernon
15Arrayed CRISPR assay to evaluate DNA damage response following PARP inhibition
Dr Richard Hewer
16In vitro characterisation of novel GPR55 agonists with nanomolar human and rat potency and differential desensitisation profile
Dr Tunmise Eugene-Osoikhia
University of East Anglia
17Synthesis, antimicrobial and computational studies of natural products derivatives of tricarbonyl (2-methoxycyclohexadienyl)iron tetrafluoroborate salt: An alternative route to natural products modification
Dr Dr Kalicharan Sharma
Delhi Pharmaceutical Science and Research University
18Design, synthesis and evaluation of novel heterocyclic compounds as Antitubercular agents
Mr Tom Raes
Sanofi Ghent
19Steel vs. Plastic – Implementation of reusable tips in an automated liquid handling platform
Dr Antonio Quílez
20“CYTOCHECK SPAchip® pH detection kit” as a new reliable method for measuring intracellular and extracellular pH in cell cultures.
Miss Antonia Molloy
Aston University
21Applying Droplet Fluidics to Mycobacterial Drug Discovery.
Dr Sunil Kumar
LR Institute of Pharmacy
22Immunomodulation-Mediated Anticancer Activity of a Novel Compound from Brugmansia suaveolens Leaves
Ms Karine Enesa
24High throughput platform for the generation of physiologically relevant and highly validated edited cell lines
Ms Lisa Bamber
25Accelerating Drug Discovery with Abcam’s Premium Bioactive Proteins
Michelle Newman
Genedata AG
26Cardiosafety Testing Based on CiPA - at Scale with SyncroPatch 384 and Genedata Screener
Miss Hannah Jennings
27Improved Sustainability Through the Use of Assay Ready Cells to Support Ion Channel Screening
Dr Matteo Bessi
28TRPML1 antagonists: Exploring new therapeutic opportunities for cancer
Dr Tatiana Rosenstock
Sygnature Discovery
29Building a Neuroscience Drug Discovery Platform
Dr Mamatha Nijaguna
Institute for Bioengineering of Catalonia (IBEC), Barcelona
30Inhibiting Mechanotransduction as a novel approach for Oncology therapy
Hosting a Presentation!
Profile Poster  
Mrs Joanne Walter
Fida Biosystems ApS
31Linking Structure and Function – Use of PDB data as baseline for in-solution characterization
Dr Merve Mutlu
Novartis Institutes for BioMedical Research
33A multi-parametric vector approach for target prioritization of CRISPR screens
Ms Gehad Mohamed
Keele University
34Inhibition of BCKDK to increase the sensitivity of breast cancer cells to paclitaxel
Hosting a Presentation!
Profile Poster  
Miss Samiyah Ahmed
35Recombinant Protein Production For Drug Discovery at Astrazeneca
Dr Natalie Russi
Nebion AG
36Unchaining the full potential of public single-cell RNA-Seq data
Hosting a Presentation!
  Profile Poster  
Mr Christian Parker
37A Validation Process for Putative Target Genes Identified by Genome-wide CRISPR-Cas9 Screening
Dr Kate Stuart
PhoreMost Ltd
38Drugging the Undruggable for the benefit of humankind: PhoreMost Ltd
Dr Andrew Lim
University of Cambridge
39A simple, homogeneous and cheap fluorescence polarisation (FP) assay to identify compound aggregators from hit discovery programmes
Dr Matthew McGoldrick
Casueway Sensors
40Addressing the problem of IgG quantification in biologics
Dr Jon Popplewell
41Improving the screening, selection and deep characterization of biotherapeutic molecules using high-throughput SPR
Dr Dean Hammond
Genedata Ltd
42AI Driven Automation of Model Selection and Data Quality Control in SPR Production Screens
Miss Loren Waters
Medicines Discovery Institute, Cardiff University
43The development and characterisation of cellular assays for measuring the effects of LIMK1 inhibitors.
Dr Alireza Azimi
44High content Platform for Image Based Screening
Dr Fernanda Ricci
Axxam SpA
45An integrated platform for drug screening of neurological disease models
Miss Mari Davies
Cardiff University
46Acid ceramidase inhibition as a mechanism to treat lysosomal storage disorders.
Dr Lars-Eric Fielmich
HUB Organoids
47Developing a patient-derived organoid biobank suitable for large scale drug screenings
The University of Nottingham
48A Villains and victims – Deciphering the impact of cell- and mutation-type on cardiac fibrosis using hIPSC derived cardiovascular models.
Dr Benjamin Moore
Excellerate Bioscience
49Kinetic phenotyping of cellular morphology, proliferation and motility using quantitative phase imaging ptychography.
Miss Lois Lewis
Medicines Discovery Institute
50Targeted Degradation of Pathogenic Protein Aggregates
Dr Alessandro Scandurra
51New fluorescent tools to evaluate the therapeutic potential of phytocannabinoids
Hosting a Presentation!
Profile Poster  
Miss Amber Ward
52Kinetic Live-Cell Visualization and Quantification of Cell Migration
Dr Frank Weise
Natural and Medical Sciences Institute
53Patient-derived in vitro models serve as a preclinical test system for personalized therapy and drug development in an animal-free setup
Ms Ziva Rejc
NMI TT Pharmaservices
54Cardiac Safety Pharmacology: Increased predictivity with laser-induced action potential like cardiac action potential recordings on MEA systems
Dr Sophie Bennett
56Biophysical Techniques for Target Engagement and Mechanism of Inhibition Studies During Small Molecule Drug Discovery
Dr Niamh Mullooly
57Recycling and re-analysis of archived CRISPRn image sets identifies novel regulators of genome integrity
Dr Carla Verissimo
HUB Organoids
58Patient derived organoids to predict clinical response: a patient in the lab
Dr Ana Veloso
Singleron Biotechnologies GmbH
59SynEcoSys: a standardized scRNAseq database for clinical translation
Dr Lambert Montava Garriga
60High-dimensional arrayed CRISPR screens to deliver mechanistic insights and prioritise targets in ER+ breast cancer.
Dr Sylviane Yoba
61Identification of new, efficacious inhibitors of DNA-PK and their hypoxia activated pro-drugs
Mr Noah Harrison
Evariste Technologies
62Improving protein-ligand docking with an automated pre-processing and constraint generation pipeline
Mr Sam Bourne
63High density profiling of the association of two-pore domain potassium ion-channel gene variants with pain
Dr Yu-Kai Chao
64Catch me if you can: Better characterizing slow-onset compounds’ liability using the “Extended hERG” automated patch-clamp assay
Dr Maja Petkovic
65KRAS nucleotide exchange assays for inhibitor screening and profiling
Miss Eleanor Godsman
Cancer Research Horizons
66Evaluating tight binding small molecule inhibitors using the Morrison equation
Ms Johanna Pott
HUB Organoids
67Patient-derived Organoids as a relevant tool for preclinical IBD research and drug development.
Dr David Howard
Swansea University
68Realising the Therapeutic Potential of Dinaciclib in Gynaecological Cancers
Dr Thomas Jones
69Development of a multiparametric cell imaging assay to assess inverse regulation of cancer associated biomarkers
Mr Yannick Nossin
Cell Signaling Technology
70High-Content Imaging Enables Efficient Discovery of Highly Specific Antibodies with Utility in Cell-Based Immunofluorescence Assays
Dr Eve Corrie
Medicines Discovery Catapult
71Methods to Examine Neuronal Morphology and Function in Human iPSC-derived Disease Models
Miss Rebecca Kelly
Medicines Discovery Catapult
72Multimodal advanced microscopy to study drug responses in complex cells models.
Ms Janne Wiedmann
Karlsruhe Institute of Technology
73Combining Miniaturized Chemical Synthesis with Biochemical Screening for High-Throughput Drug Development
Mr Maximilian Seifermann
Karlsruhe Institute of Technology
74Combinatorial Solid-Phase Synthesis of Proteolysis Targeting Chimeras for High-Throughput Cell Screening on Droplet Microarray
Ms Essi Niemi
UPM Biomedicals
75Automated 3D Cell-Based Assays in Animal-Free Nanofibrillar Cellulose Hydrogels for High-Throughput Screening Analyses
Mr Julius Höpfner
Karlsruhe Institute of Technology
76Parallel and Miniaturized Combinatorial Synthesis and Subsequent Analysis of Small Molecules using Droplet Microarrays
Dr Gemma Holliday
Medicines Discovery Catapult
77A journey from Protein to Compound: Virtual Screening @ MDC
Dr Alessia Serrano
78Arrayed CRISPR KO screens in renal cell models enable the identification of novel targets for Chronic Kidney Disease
Dr Samuel Kerr
Singleron Biotechnologies
79A High-Throughput RNA-seq Method For Efficient Drug Screening
Mr Kieran Casey
80Modelling Liver Disease Using CRISPR Edited Human Induced Pluripotent Stem Cells
Hosting a Presentation!
Profile Poster  
Miss Maria Clapés
SUN bioscience SA
81Modelling inflammatory bowel disease in human intestinal organoids using a high-throughput workflow
Miss Maria Clapés
SUN bioscience SA
82A microwell platform to standardize human rectal organoid cultures for high-content imaging and phenotypic analyses
Dr Charlie Dunlop
83Arrayed CRISPR screening in primary human Tregs using a multi-colour flow cytometry endpoint
Dr Rosie Waters
84Synthesis and profiling of novel GPR39 agonists and positive allosteric modulators
Mr David Cadwalladr
85Identification and isolation of human striatal cell types using flow cytometry methods as part of Cerevance’s NETSseq platform
Dr Aadarash Zia
Medicines Discovery Catapult
86Efficient intracellular delivery of nucleic acids by NUVEC® silica nanoparticles
Ms Holly Cooper
87Characterising the Biochemical Mechanism of Action of PolQ Inhibitors
Mr Martin Wegner
Vivlion GmbH
88Optimized CRISPR-Cas screening at scale with Vivlion
Dr Chloe Whitehouse
89Developing a scaffold-based model of neurodegeneration for high throughput screening
Dr Joanne Usher
90Measuring mitophagy and mitochondrial dysfunction in neurodegeneration
Miss Christine C Yu
Gifford Bioscience Ltd
91Avidity vs Affinity: A Common Biosensor Problem or an Advantageous Biological Mechanism?
Ms Elizabeth Fraser
92Standardized, bioprocessed organoids enable automated platforms for high-throughput drug discovery
Dr Joseph Williams
Cellesce Limited
93Biological insights into 3D organoids using a modular, scalable and data efficient image analysis pipeline
Dr Celine Legros
Eurofins Discovery
94Identification and Validation of Novel and Tractable PIM3 Starting Points and their Optimisation
Eurofins Discovery
95Novel Multiple Targeting Monitoring by Label-Free Binding by Mass Spectrometry Directly in Tissue For Translational In Vitro Safety-Tox Studies.
Dr Michael Eyres
Medicines Discovery Catapult
96Whole transcriptome digital spatial profiling of pain-induced DRGs
Dr Stuart Prime
Axol Bioscience Ltd
97Development Of 2D And 3D Functional Platforms for integrated Neuromuscular Studies
Miss Sareena Sund
University of Birmingham
98Novel 355nm (and Lower) Excitable and Tuneable Emission (Blue through Red) Fluorophores Utilised in Flow Cytometry
Dr Farzin Pourfarzad
HUB Organoids
99Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy development
Dr Jessica Tilman
Axol Bioscience
100Generating iPSC derived alveolar macrophages as a novel model for respiratory research
Dr Sara Kanje
Pelago Bioscience
101How to tackle difficult targets in CETSA® Navigate
Dr Paul Russell
Horizon Discovery
102A Base Editor Screening Platform to Characterize Performance of the Modular Components of Horizon’s Pin-Point Base Editing System.
Dr Joao Pisco
103Characterisation and inhibition of nsp14, a potential pan-coronavirus target
Dr Alex Roberts
Sygnature Discovery
104Investigating B lymphocyte signalling pathways through PhosFlow
Dr Maxime Couturier
105Decreased assay development timelines and improved productivity and sustainability by implementation of High Dimensional Experimentation
Mr Gareth Fenn
Medicines Discovery Institute, Cardiff University
106Development of a novel anthraquinone derived fluorescent lysosomal probe
Dr Adedamola Olayanju
Manchester BIOGEL
107Tuneable Synthetic Peptide Hydrogels to provide Physiologically and Clinically relevant in vitro 3D cultures
Miss Chloe Tayler
108Mass Spectrometry in Drug Discovery: Investigating Ion Suppression across Screening Platforms
Miss Amy Burton
109Title: Utilising Echo® MS as a mass spectrometry- based assay technique to screen for Acetylcholinesterase inhibition
Dr Omar Qureshi
110P2X7 receptor mediated cytokine release from human microglia (monocyte-derived) and precision-cut brain slices; implications for patients with TBI and other brain pro-inflammatory conditions
Dr Omar Qureshi
111A cell-based spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants
Mrs Patricia Villace
112NOMAD®Genetically encoded biosensors for multiplexing PAR2 protease-activated receptor functional assay
Mrs Patricia Villace
113TDP43/FUS Fluorescence cell-based assay to screen synergistic drugs against ALS disease
Ms Michelle Irving
Nexcelom from PerkinElmer
114Cell identity, count, and viability for critical quality attributes using the Cellaca PLX image cytometer
Ms Michelle Irving
Nexcelom from PerkinElmer
115Large-batch consistency evaluation of cell counting instruments used in cell therapy applications
Dr Amina McDiarmid
University of Edinburgh
116Morphological profiling by cell painting in human neural progenitor cells classifies hit compounds in a pilot drug screen for Alzheimer’s disease
Hosting a Presentation!
Profile Poster  
Ms Anna Willms
117Automated Classification of Single Cell Colonies into Holo-, Mero- and Paraclones using CELLAVISTA and YT-SOFTWARE
Miss Leonie Mueller
Newcastle Univeristy
118Development of a high-throughput MALDI-TOF MS drug discovery assay for ERAP1
Miss Julie Vann
Charles River
119Screening multiple PPI targets in parallel: accelerating portfolio-level decisions
Ms Wiebe Schaefer
120Analyzing Cytotoxicity in a 2D and 3D Colorectal Cancer Model using an Automated High Content Imaging System
Dr Patrick McIntyre
Charnwood Molecular
121Using SPR to Characterise the Binding Modes of PROTAC Molecules
Dr James Chamberlain
Charnwood Molecular
122Expanding Live-cell Imaging Capability at Charnwood Molecular – Investigating 3D Tumour Spheroids and Immune Cell Models with the IncuCyte SX5
Dr Ryan Mordue
Charnwood Molecular
123Protein detection Capabilities – How to push forward your hit to lead program
Mr David Whalley
Discovery from Charles River
124SARS-CoV-2 MPro Assay for Discovery and Characterisation of Active SARS-CoV-2 Inhibitors
Dr Michael Goldsmith
Charles River Laboratories
125Design of selective chemical probes for the serum and glucocorticoid-regulated kinase SGK3
Dr Arnold Sienerth
Charles River Laboratories
126A Huntington’s disease embryonic stem cell phenotypic HTS to identify small molecule modulators of mutant huntingtin
Mr Joseph Bradley
Scitegrity Limited
127Compliance Hub for Drug Discovery
Dr Thomas Miller
Charnwood Molecular
128Using SPR to drive integrated screening projects
Mr Oliver Medhurst
129Proof of concept for discovering allosteric kinase inhibitors by characterising a MEK1 type III kinase inhibitor using a fluorescent ATP analogue
Dr Simon D'Archivio
Sygnature Discovery
130Development of an in vitro model for Human T cell exhaustion
Dr Emma Jones
Medicines Discovery Catapult
131Drug discovery tools to examine neuroinflammation signalling in human iPSC-derived microglia 
Dr Kirill Popov
Red Glead Discovery
132Exploring the bromodomain of SMARCA4 (BRG1) by Weak Affinity Chromatography (WAC™)
Dr Jeff Shi
133MCE- master of bioactive molecules
Dr Wolfgang Fecke
134Accelerating small molecule drug discovery by a powerful collaborative approach A
Miss Liya Indrias
135New organoid scaffold with fibrillar collagen, laminin, and hyaluronic acid
Dr Katherine Czysz
Fujifilm Cellular Dynamics, Inc.
136Generation of a Blood-Brain Barrier Model using Cryopreserved Human iPSC-Derived Brain Microvascular Endothelial Cells, Pericytes, and Astrocytes
Dr Andrew Scott
Concept Life Sciences
137Harnessing the Biophysical Fragment Screening Sweet Spot to Discover New Chemotypes for BRPF1 Inhibition
Mr Alex Phillipou
138Cellular Target Engagement Approaches to Monitor Epigenetic Reader Domain Interactions.
Mr Steven Trim
Venomtech Limited
139Assaying complex 3D tissues in microplates, learning from fluorescent scorpions
Miss Tamsin Chowdhury
Charles River Laboratories
140Pilot study to compare a traditional HTS approach with AI-driven compound selection for the identification of kinase inhibitors
Dr Trevor Askwith
141The new kids on the block: Fragment screening using Temperature Related Intensity Changes and Grating Coupled Interferometry
Dr Emily Richardson
CN Bio Innovations
142Evaluation of in vitro human alveolar and bronchial microphysiological systems to predict the permeability and absorption of inhaled pulmonary medications.
Dr Sree Vadlamudi
143Deep Generative modelling for structure-guided de novo drug design
Dr Ilaria Proietti Silvestri
Liverpool ChiroChem
1443Discovery platform: boosting hit-identification and lead-optimisation efficiency by merging fragment screening, virtual screening, parallel synthesis and chirally pure chemical space
Dr Raphael Tomasi
145Okomera: Functional Precision Medicine Enabled by Droplet Microfluidics
Dr Raphael Tomasi
146Combinatorial Drug Screening on 3D Ewing Sarcoma Spheroids Using Droplet-Based Microfluidics
Dr Mohammed Azim
Excellerate Bioscience
147Luciferase Complementation Approaches to Measure GRK2 Recruitment to GPCRs
Dr Sarah Northall
148An AMI-MS assay enables biochemical profiling of novel hydrolase inhibitors
Mr Restuan Lubis
Lead Discovery Center
149A sensitive, homogeneous, and high-throughput assay for homologous recombination DNA repair (HRR) modulators using the engineered luminescent enzyme
Mr Restuan Lubis
Lead Discovery Center
150A successful high-throughput screening campaign for new small molecule inhibitors of BLM Helicase
Miss Eleanor Platt
Medicines Discovery Catapult
151Understanding the Senolytic and Senomorphic Effects of Zoledronate in an Ageing Mouse Model
Dr Mariangela Iovino
Discovery from Charles River
152Characterization of a human iPSC derived Huntington’s disease cell line suitable for disease modelling and drug screening
Dr Natalia Dovlatova
Platelet Services Ltd.
153The role of platelet function and viability testing in addressing observations of suspected drug-induced thrombocytopenia
Dr Malathi Raman
154Fast, reproducible and scalable generation of functional microglia from hiPSCs for neuroinflammation and neurodegenerative disease research & drug development
Dr Egle Vaitone
155High-content imaging-based profiling of ion channel gene expression and function in primary cultures of rodent dorsal root ganglion and trigeminal ganglion cells
Dr Karla Paterson
156ONCO-Chip3D: facilitating physiologically relevant drug and cell therapy screening in complex 3D tumour models
Dr Irma Berrueta Razo
MDC Catapult
157Investigation of lipid biomarkers in Amyotrophic Lateral Sclerosis using Mass Spectrometry Imaging
Dr Leigh Stoddart
Excellerate Bioscience
158Integrating signaling kinetics into GPCR compound profiling
Dr Gareth Langley
Charles River Laboratories
159Avoid the fear of missing out: Early, thorough assessment of assay translation is crucial in dictating screening strategy and reducing the risk of false negatives
Dr Eider Valle-Encinas
HUB Organoids
160Development of a medium-to-high throughput organoid and bacteria co-culture platform for the assessment of host pathogen interaction
Miss Liya Indrias
161Cryopreserving freshly isolated smooth muscle cells for large scale analysis at the single cell level
Miss Liya Indrias
162Novel 3D Hydrogel System Enhances Regenerative Capacity of Stem Cells and Improves Tailorability of Biologics
Miss Liya Indrias
163Primary rodent hepatocyte isolation and culture with GMP and research-grade enzyme blends
Dr Joel Cresser-Brown
Tocris / Bio-Techne
164Validating Targets for TPD using dTAG – a comprehensive workflow solution
Dr Dinesh Kumar
Drug Discovery Unit, School of Life Sciences, University of Dundee, UK
165Targeting the α1-subunit of AMPK by selective protein degradation as a potential new treatment in cancer.
Dr Sarah Whipple
166Development of assay systems to aid in the fight against chronic neuroinflammation
Hosting a Presentation!
Profile Poster  
Dr Lyn Parkinson
Sygnature Discovery Ltd
167High-Throughput Screening at Sygnature Discovery- the Story so Far…
Dr Kay Osborn
University of Sussex
168Developing Stable cell lines with Combinatorial Kv subtypes for Drug discovery.
Dr Magdalena Otrocka
169Multimodal Approach to MoA Prediction Based on Cell Painting Imaging and Chemical Structure Data
Miss Evangelia Kounatidou
170Fully Functionalised Fragments (FFFs) go Viral: A large-scale screen to identify Newcastle Disease Virus (NDV) potentiators
Dr Ovidiu Novac
CN Bio Innovations Ltd. UK
171Evaluating different modalities of drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers
Dr Allan Jordan
Sygnature Discovery
172“The Sygnature CHARMD Platform: Combinatorial High-throughput Assembly and Review of Molecular Degraders”
Dr Pawel Leznicki
Sygnature Discovery
173Mass spectrometry-based detection of ligand binding to membrane-embedded receptors.
Dr Raminderpal Singh
174ALaSCA: A system for prioritising experimental design in early drug discovery and medical device product development, using causal analysis
Hosting a Presentation!
  Profile Poster  
Dr Guido Zagnoli Vieira
175Laser Microirradiation Assay: Tracking DNA Damage Response (DDR) kinetics
Dr Victor Wong
Core Life Analytics
176Get Ready for JUMP-CP: Analysis of a Pilot Data Set Reveals Critical Insights for Platform Development.
Miss Catriona Corbishley
AstraZeneca & University of Cambridge
177Target Tractability Assessment Using DNA-Encoded Library Screening
Dr Christophe Parsy
Agg. Prof. Antonella Ragnini-Wilson
University of Rome Tor Vergata
179Multidisciplinary approaches to change the landscape horizon of remyelination therapieser Abstract
Dr Shikta Das
180Genomic analysis using 455,000 UK Biobank exome sequences to identify candidate drug targets
Dr Karthi Rajamani
Takara Bio Europe
181Next-generation human iPS cell-derived hepatocytes for metabolic disease modeling and drug discovery
Dr David Egan
Core Life Analytics
182Image-based phenotypic profiling using Cell Painting in a 3D breast cancer spheroid model.
Mr Oliver Vipond
Evariste Technologies
183Explaining the Sensitivity of DepMap Cell Lines to CRISPR Knockdown
Mrs Kavita Raniga
GSK & University of Nottingham
184Development of a multiparametric cardiovascular toxicity assay using iPSC derived cardiomyocytes, endothelial cells, and primary cardiac fibroblasts
Dr Samantha Kanza
University of Southampton
185Poster: The Physical Sciences Data Infrastructure (PSDI)